araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer

Summary: The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.

Detailed description: There is currently no strong prognostic factor in pancreatic cancer. K-ras is the most commonly mutated gene in pancreatic cancer, with a mutation rate of 75% to 95%. These high mutation rates are expected to be useful for diagnosis and prognostic factors in future. Currently, K-ras mutation tests are often performed in tissues, and there are various limitations, in particular, limited obtaining of sufficient tissues. In this regard, analyzing the prognosis of pancreatic cancer through non-invasive blood testing has significant advantages. And Prognosis analysis through blood tests can be done through blood circulating tumor DNA. The relationship between prognosis and blood circulating tumor DNA has already been studied in other cancers such as colorectal cancer, and there have been several studies in pancreatic cancer. However, there are not many research results yet, and there are cases in which the results differ from study to study. Therefore, the purpose of this study is to compare the overall survival of patients with pancreatic cancer diagnosed by EUS-FNA according to the presence and amount of blood circulating tumor DNA with K-ras mutation.

Eligibility: Inclusion Criteria:
  -  Patients diagnosed with pancreatic cancer through EUS-FNA.
  Exclusion Criteria:
  -  Severe mental illness
  -  Severe co-morbidity (ESRD, Advanced COPD, severe Heart failure, poorly controlled blood sugar)
  -  Pregnancy
  -  Patients who have received chemotherapy
  -  Coagulopathy

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Prospective Cohort Study of Variant Carriers With BRCA1 or BRCA2

Summary: To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.

Detailed description: 1. To estimate the incidence of ovarian, fallopian tube and peritoneal cancers in women carrying BRCA1/2 variants.
  2. To investigate risk factors concerning the development of ovarian, fallopian tube, and peritoneal cancers (loci of BRCA1/2 genetic variants, modifier genes, genetic polymorphism, hormones, and lifestyle habits.) in women carrying BRCA1/2 variants.
  3. To estimate the detection rates of occult cancer based on histopathological evaluations, using risk-reducing salpingo-oophorectomy (RRSO).
  4. To examine the risk-reducing effect of RRSO on the development of ovarian, fallopian tube, and peritoneal cancers in women carrying BRCA1/2 variants, and compare with those not undergoing RRSO.
  5. To identify clinicopathological features in women carrying BRCA1/2 variants who had undergone RRSO.
  6. To identify the appropriate interval or degree of surveillance.

Eligibility: Inclusion Criteria:
  1. Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).
  2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.
  3. Women who provide consent should be 20 years of age or older.
  4. Women who provide written consent.
  Exclusion Criteria:
  1. Women without ovarian or fallopian tube cancer at the time of informed consent.
  2. Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.
  3. Other individuals considered inappropriate for involvement in this study by the investigator.

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: PENS or TENS for Pain in Pancreatic Cancer

Summary: This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with pancreatic cancer. Patients will randomly allocated into PENS group, Tens group and control group.

Detailed description: PENS and TENS have been reported with analgesic effect in patients with pain, including cancer pain, lower back pain, neck pain, stomachache and so on.
  Effect and mechanism of PENS on pain relieving has been widely researched. With additional electrical stimulation in certain frequency and intensity to conventional acupuncture, pain controlling effect has been largely enhanced. However, invasive operation limits its application and acceptability, especially on pancreatic cancer.
  TENS is an advanced technique generated from PENS, which is much more welcome for its noninvasive character. Further more, its analgesic effect on cancer pain has been proved by several multi-central, randomized, clinical trials.

Eligibility: Inclusion Criteria:
  -  Pancreatic cancer with pain;
  -  Haven't underwent neurolytic celiac plexus block in the past 1 month;
  -  With anticipatory survival of more than 3 months.
  Exclusion Criteria:
  -  Metastatic pancreatic cancer;
  -  Can not tolerate 30 min of lieing in prostrate or side position;
  -  PS>3;
  -  Who has been recruited in other clinical trial for pain releiving;
  -  Who underwent radiotherapy or local radiactive seeds implantation for pain releiving in the past month;
  -  Imaging diagnosed with encephalic tumor or metastasis;
  -  Who with cardiac pacemaker or metal stand;

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery

Summary: Investigators asses whether there is any difference in short term recovery and long term prognosis according to the anesthetic method in patients who undergoing pancreatic cancer and bile duct cancer and undergoing surgery for PPPD or distal pancreatectomy.


Eligibility: Inclusion Criteria:
  -  Patients with ASA class I-III who are scheduled to undergo general anesthesia and who are diagnosed with pancreatic cancer or common bile duct cancer and who are scheduled for PPPD or distal pancreatectomy
  -  patients who voluntarily agree to participate the clinical study after fully informed and understood about the study
  Exclusion Criteria:
  -  there was distant metastasis at the time of diagnosis
  -  history of drug adverse reaction or use of opioid or sedative drugs before the surgery
  -  patients who can not communicate enough to answer the survey
  -  obesity patients over BMI 30
  -  patient who are expected to maintain ventilator care on the first day of post operation due to the difficult to extubation right after the surgery
  -  patients who have inappropriate reasons to participate in clinical research

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

Summary: The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical role in the development and progression of pancreatic cancer. Here we intend to assess the synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0 resection of pancreatic cancer.

Detailed description: We choose those patients who had underwent the R0 resection of pancreatic ductal adenocarcinoma patients, and divided them into two groups randomly, one group patients were given gemcitabine only according the current guidelines, while the other group patients were given gemcitabine combined with the anti-inflammation agent Celecoxib. The disease free survivals, drugs related side effects, overall survivals and other endpoints events were recorded and analyzed, to assess the celecoxib could or couldn't synergist the gemcitabine anti tumor effect on R0 resection pancreatic cancer patients.

Eligibility: Inclusion Criteria:
  1. 18 years old and above.
  2. Surgery for R0 resection.
  3. The gemcitabine chemotherapy regimen was not previously used for the treatment of other malignancies.
  4. Eastern Cooperative Oncology Group score 0-2 points.
  5. Blood routine: The neutrophil count is at least 1.5*10^9/ml, and the platelet count is at least 100*10^9/ml.Hemoglobin is at least 80g/L.
  6. Liver function: bilirubin does not exceed 1.5 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase does not exceed the upper limit of normal 3 times; kidney function: creatinine ≤ 1.2 mg/dL.
  Exclusion Criteria:
  1. Endocrine carcinoma, acinar pancreatic carcinoma, or cystadenocarcinoma (cystadenocarcinoma).
  2. Surgery for pancreatic cancer fails to reach the R0 resection criteria.
  3. Pancreatic cancer received radiotherapy before surgery.
  4. Malignant brain metastases.
  5. There are other serious cancer history.
  6. Active infection, severe diarrhea.
  7. Others: Those who are allergic to celecoxib; or who are intolerant to celecoxib, require continuous aspirin or Non-steroidal anti-inflammatory drugs; similar chemical or biological components and sulfa drugs that constitute the study drug History of allergies; allergies, asthma, and rubella after taking aspirin or non-steroidal anti-inflammatory drugs; pregnancy or breastfeeding; active gastrointestinal ulcer/hemorrhage/perforation; Severe mental illness; severe heart failure; past serious cardiovascular thrombotic adverse events, severe hypertensive patients.

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Genetics and Heart Health After Cancer Therapy

Summary: The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease


Eligibility: Inclusion Criteria
  -  ≥18 years of age
  -  Initial diagnosis of Breast Cancer in 2005 or later
  -  Documented BRCA testing (results from a local laboratory are acceptable) showing
  -  confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted or suspected to be deleterious OR
  -  confirmation that no mutation was detected in BRCA1 or BRCA2
  -  Non-carriers will have been treated with an anthracycline-based chemotherapy regimen; carriers may or may not have been treated with an anthracycline-based chemotherapy regimen.
  -  Approximately at least 12 months from initiation of adjuvant treatment or neo-adjuvant chemotherapy
  -  Able to provide informed consent
  Exclusion Criteria
  -  Stage IV Breast Cancer
  -  Genetic testing confirming a variant of unknown significance (VUS) or benign polymorphism in BRCA1 or BRCA2
  -  V02 Testing contraindicated for any reason, including:
  -  Myocardial infarction (within past 3 months)
  -  High-risk unstable angina;
  -  High-risk or uncontrolled cardiac arrhythmias;
  -  Symptomatic severe aortic stenosis;
  -  Uncontrolled symptomatic heart failure;
  -  Acute pulmonary embolus or pulmonary infarction;
  -  Acute myocarditis or pericarditis;
  -  Acute aortic dissection;
  -  Coronary revascularization procedure within the past three months;
  -  Uncontrolled hypertension, defined as systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg;
  -  Clinically significant valvular heart disease (severe stenosis or regurgitation);
  -  Known aortic aneurysm; or
  -  Any other condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the V02 test
  -  Women who are pregnant
  -  Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Urinary TF and Endo180 in Early Pancreatic Cancer Detection

Summary: This study will measure the levels of uTF and Endo180 in patients with pancreatic cancer, and also in patients with pancreatic cysts in which cancer may be suspected, to determine the accuracy of these tests in detecting early stage pancreatic cancer. The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pancreatic cancer, at a stage where surgery is feasible, would greatly increase the 5-year survival rate. Detecting pancreatic cancer early is therefore vital to improve the prognosis for these patients.
  Precancerous pancreatic cysts are an early indicator of malignant transformation. The ideal screening test would be capable of detecting pancreatic cancer at these initial stages. Current procedures for pancreatic cancer diagnosis are invasive, uncomfortable and costly, and can be considered unnecessary in those cysts found to be benign.
  The investigators propose two potential markers of early pancreatic cancer: urinary tissue factor (uTF) and Endo180. ELISA tests have been developed to measure the levels of TF in urinary microvesicles and Endo180 concentration in urine, serum and cystic fluid samples.


Eligibility: Inclusion Criteria:
  General
  -  Capable of giving written informed consent
  -  Age ≥18 years
  Pancreatic Cancer Cohort
  - Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or Whipple's procedure).
  OR - Diagnosed with inoperable localised pancreatic cancer and referred for further management (malignant control subgroup).
  Pancreatic Cysts Cohort
  - Presence of cystic lesions where MDT have agreed further diagnostic intervention procedures (including FNA/EUS) necessary.
  OR - Patient the MDT have agreed have resectable lesions suspicious for pancreatic malignancy and going to surgery.
  Benign Cohort
  - Referral for endoscopic cystogastrostomy for complicated acute pancreatitis characterised by peripancreatic fluid collections and pseudocysts in development or matured (non-resolving and requiring further intervention).
  OR
  -  Referral for cholecystectomy for cholocystitis/chololethiasis. OR
  -  Patient had cholecystectomy 8 weeks earlier (normal control subgroup).
  Exclusion Criteria:
  General
  -  Inability to provide written informed consent
  -  Other known malignant condition, either active or in complete remission ≤5 years
  -  HIV, hepatitis C, or any other known communicable disease

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Blood Markers of Early Pancreas Cancer

Summary: Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
  The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Detailed description: Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) have only an 8% chance of surviving 5 years after diagnosis. Most PDAC is advanced and not amenable to curative therapies at the time of diagnosis, owing to lack of symptoms in early disease, nonspecific symptoms when they do develop resulting in a delay in diagnosis. Identifying biomarkers of early PDAC could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.
  The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens. Subjects will include individuals with family history of pancreas cancer, individuals with cystic pancreas lesions or chronic pancreatitis, and individuals with new-onset diabetes. Identifying specific biomarkers - blood markers and/or a clinical "prodrome" - in participants who go on to develop PDAC could improve the diagnostic approach outcomes for patients diagnosed with PDAC.

Eligibility: Inclusion Criteria:
  General inclusion criteria:
  1. Age ≥19
  2. Able to provide written, informed consent
  Exclusion Criteria:
  General exclusion criteria:
  1. Personal history of PDAC
  2. Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
  3. Pre-diabetes on metformin for ≥ 3 years

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

Summary: To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis. In addition to test the potential treatment target of acute pancreatitis.
  All patients who present with clinical symptoms of acute pancreatitis are evaluated for the enrollment of the study.

Detailed description: All patients with acute pancreatitis are evaluated according to modified Atlanta classification acute pancreatitis severity scores.
  Blood serum, urine and DNA samples are collected from all patients presented on admission, after 24 hours, 48 hours, 72 hours.
  CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital admission. If necrosis is not present follow-up is stopped.

Eligibility: Inclusion Criteria:
  -  no prior diagnosis of acute pancreatitis
  -  admission to the hospital within 2 days since the clinical symptoms
  -  confirmed diagnosis of acute pancreatitis
  Exclusion Criteria:
  -  chronic pancreatitis
  -  pancreatic cancer

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

Summary: Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers

Detailed description: Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers

Eligibility: 1. Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.
  1. Woman with or without breast cancer or ovarian cancer at baseline.
  2. Man with or without breast cancer at baseline.
  2. Signed consent to participation
  3. Affiliation to a social security regimen, or beneficiary of such a regimen.
  Exclusion Criteria:
  1. A person of legal age subject to a legal protection measure, or unable to express consent.
  2. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

Summary: This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer. Ultra-high resolution optical coherence tomography may help to accurately identify pancreatic cancer in resected pancreatic specimens.

Detailed description: PRIMARY OBJECTIVES:
  I. To evaluate the using of optical coherence tomography (OCT) to diagnose pancreatic cancer arising in the setting of intraductal papillary mucinous neoplasms (IPMN) using the resected pancreatic specimen.
  II. To correlate OCT imaging diagnosis with histologic findings in the human pancreatic duct.
  IPMN is a premalignant lesions arising in the pancreas. Typically, IPMNs are identified incidentally on imaging performed for other reason or related to vague abdominal pain or gastrointestinal complaints. In terms of IPMN, invasive cancer can be found in this setting between 20 to 50% of the time[7] Therefore, if a patient is diagnosed with IPMN, especially main duct type, the general recommendation is to undergo resection. We propose to assess the duct of the pancreatic specimen after resection to identify evidence of invasive malignancy by OCT imaging. Afterwards, the specimen will be undergoing histopathologic assessment using standard protocols. Our hypothesis is that OCT will accurately identify pancreatic cancer in resected pancreatic specimen. The assessment with OCT is non-invasive and will not harm to change the specimen prior to going to pathology for standard review. Future studies will then focus on using this imaging technique in vivo to endoscopically identify early stage pancreatic cancer.

Eligibility: Inclusion Criteria:
  -  Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN
  -  Immediate surgery cohort: Informed consent will be obtained
  -  Adult patients undergoing pancreatic resection for a presumed IPMN
  Exclusion Criteria:
  -  Pregnant

Relevance to patient case: not relevant
Patient case: 50-year-old male with pancreatic cancer; genetic feature: BRCA2

Clinical trial: Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry

Summary: This pancreatic cancer registry aims to collect information on people around the world who select focused ultrasound (FUS) as part of their treatment for pancreatic cancer to learn about the performance of the focused ultrasound technology and health outcomes; the impact of focused ultrasound on your overall health; and provide an understanding of the current care for pancreatic cancer.

Detailed description: The purpose of the registry is to collect data on the performance of the focused ultrasound (FUS) technology and health outcomes. A wide variety of approaches exist for using FUS on pancreatic cancer patients, and the primary goal is to capture this broad spectrum of approaches and their impact on patients overall health. This information will help provide a better understanding of current care, and may possibly direct further, more specific investigations that will follow this registry. After obtaining informed consent a baseline history, physical examination, laboratory studies, and imaging studies needed per standard of care will be performed. Patients' treatment is determined by their caregivers only, and thus the registry will evaluate patient management in "real-world" conditions.
  Enrollment Goal: 100
  Primary Outcomes: Pain related to pancreatic cancer, Objective response, Progression-free and overall survival, Performance Status, Clinical Benefit Response (CBR), Health-related quality of life

Eligibility: Inclusion Criteria:
  -  Provision of signed and dated informed consent form
  -  Stated willingness to comply with all registry procedures and availability for the duration of the registry
  -  Histology proven pancreatic carcinoma in any area of pancreas
  -  Pancreatic tumor that can be treated by FUS
  -  Willingness and ability to complete follow-up interviews
  Exclusion Criteria:
  -  Any disease, condition or surgery which would result in a contraindication to undergoing FUS therapy.
  -  Clinical trials of pancreatic cancer not of focused ultrasound or related activities
  -  Other non-pancreatic cancer clinical trials

Relevance to patient case: not relevant